Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) PT at $30.70

Hims & Hers Health, Inc. (NYSE:HIMS) has earned a consensus rating of “Hold” from the sixteen research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $30.70.

A number of research firms have recently weighed in on HIMS. UBS Group set a $23.00 price target on Hims & Hers Health in a report on Friday, May 22nd. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Barclays raised their target price on Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research report on Wednesday, June 17th. Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a research note on Tuesday, May 12th. Finally, JPMorgan Chase & Co. decreased their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th.

Insider Activity

In related news, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the transaction, the chief operating officer owned 432,124 shares in the company, valued at $13,611,906. This trade represents a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total value of $830,410.00. Following the sale, the insider directly owned 181,861 shares in the company, valued at approximately $6,365,135. The trade was a 11.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 112,234 shares of company stock worth $3,583,793 in the last 90 days. 11.76% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently modified their holdings of HIMS. Bank of America Corp DE boosted its holdings in shares of Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after buying an additional 2,877,550 shares during the period. Farallon Capital Management LLC raised its holdings in shares of Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the period. Norges Bank purchased a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $62,153,000. Invesco Ltd. lifted its position in shares of Hims & Hers Health by 62.7% in the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after acquiring an additional 1,600,004 shares in the last quarter. Finally, Marex Group plc boosted its stake in Hims & Hers Health by 162.2% in the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock worth $78,562,000 after purchasing an additional 1,496,707 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Down 2.3%

Hims & Hers Health stock opened at $32.89 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. Hims & Hers Health has a one year low of $13.74 and a one year high of $70.43. The company has a 50-day simple moving average of $30.14 and a 200-day simple moving average of $26.40. The firm has a market capitalization of $7.61 billion, a P/E ratio of -365.44, a P/E/G ratio of 92.42 and a beta of 2.35.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.20 earnings per share. As a group, equities analysts expect that Hims & Hers Health will post 0.03 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.